

First In Human Study to Assess Safety and Efficacy of the Cham- pioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery Disease

NCT06410313

Status	RECRUITING
Phase	Not Applicable
Sponsor	Medinol Ltd.
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (10)

- Age ≥ 18 years and of age of legal consent.
- Subject has lifestyle limiting claudication or rest pain (Rutherford-Becker scale 2-4) with a resting ankle-brachial index/toe-brachial index (ABI/TBI) $\leq 0.90/0.80$.
- A single superficial femoral artery lesion with $\geq 50\%$ stenosis or total occlusion.
- Stenotic lesion(s) or occluded length within the same vessel (one long or multiple serial lesions) ≤ 150 mm.
- Reference vessel diameter (RVD) ≥ 3.0 mm and ≤ 5.0 mm by visual assessment.

... and 5 more (see full listing online)

Exclusion (29)

- Presence of thrombus in the treated vessel as visualized by angiography, prior to crossing the lesion.
- Thrombolysis of the target vessel within 72 hours prior to the index procedure, where complete resolution of the thrombus was not achieved.
- Poor aortoiliac or common femoral "inflow" (i.e. angiographically defined $\geq 50\%$ stenosis of the iliac or common femoral artery) that would be deemed inadequate to support a femoro-popliteal bypass graft and was not successfully treated prior to treatment of the target lesion either within the same procedure or at least 30 days prior to the index procedure.
- Presence of residual $\geq 30\%$ stenosis after either PTA or stenting of the inflow lesion.
- Presence of an ipsilateral arterial artificial graft.

... and 24 more (see full listing online)

Locations (7 total)

Piedmont Healthcare, Inc., Atlanta, Georgia, United States

Columbia University Medical Center/ NewYork Presbyterian Hospital or CUMC/NYPH, New York, New York, United States

St Francis Hospital Heart Center, Roslyn, New York, United States

... and 4 more locations